{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:03:43Z","timestamp":1788995023754,"version":"build-2803163510"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Data are scant on use of finerenone in diabetic kidney disease (DKD). We undertook this meta-analysis to address this knowledge gap.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Electronic databases were searched for randomized controlled trials (RCTs) involving diabetes patients receiving finerenone compared to controls. The primary outcome was changes in urine albumin-creatinine ratio (UACR). Secondary outcomes were time to kidney failure (decline in GFR by &gt;40% from baseline over 4 weeks), time to end-stage kidney disease, hospitalization for any cause, death and adverse events reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      From initially screened 79 articles, data from 7 RCTs involving 13,783 patients were analyzed (3 in active control group [ACG] defined as having eplerenone\/spironolactone as active comparator; 4 in passive control group [PCG] defined as having placebo as controls). Patients receiving finerenone had greater percentage lowering of UACR from baseline as compared to PCG [MD23.82% (95%CI: \u201324.87 to \u201322.77);\n                      <jats:italic toggle=\"yes\">P &lt;<\/jats:italic>\n                      0.01;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 96%] at 90 days, after 2 years [MD 37.9% (95%CI: \u201338.09 to \u201337.71);\n                      <jats:italic toggle=\"yes\">P &lt;<\/jats:italic>\n                      0.01] and 4 years [MD 25.20%(95%CI: \u201325.63 to \u201324.77);\n                      <jats:italic toggle=\"yes\">P &lt;<\/jats:italic>\n                      0.01] of treatment. Patients receiving finerenone has lower chance of &gt;40% decline in GFR (OR 0.83 [95%CI: 0.75 to 0.92];\n                      <jats:italic toggle=\"yes\">P &lt;<\/jats:italic>\n                      0.01;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 0%). Patients receiving finerenone had lower occurrence of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalization for heart failure, as compared to placebo\/eplerenone (OR0.86 [95%CI: 0.78 to 0.95];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 0%). TAEs was similar (RR0.97 [95%CI: 0.88\u20131.07];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.56;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 0%), but SAEs significantly lower (RR0.91 [95%CI: 0.84 to 0.97];\n                      <jats:italic toggle=\"yes\">P &lt;<\/jats:italic>\n                      0.01;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 0%) in finerenone-group compared to controls.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This meta-analysis provides reassuring data on beneficial impact of finerenone in reducing UACR and GFR decline as compared to placebo. We still lack head-to-head comparison of renal outcomes of finerenone vs eplerenone\/spironolactone in DKD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijem.ijem_376_21","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T05:29:27Z","timestamp":1659504567000},"page":"198-205","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and Safety of Novel Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in the Management of Diabetic Kidney Disease"],"prefix":"10.4103","volume":"26","author":[{"given":"Deep","family":"Dutta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineet","family":"Surana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saptarshi","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20240828","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/jdi.13355","article-title":"Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017:Estimates from Global Burden of Disease 2017","volume":"12","author":"Li","year":"2021","journal-title":"J Diabetes Investig"},{"key":"R2-2-20240828","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases:Pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int"},{"key":"R3-2-20240828","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1210\/en.2006-0944","article-title":"Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus","volume":"147","author":"Guo","year":"2006","journal-title":"Endocrinology"},{"key":"R4-2-20240828","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Konikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"R5-2-20240828","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.3748\/wjg.14.1908","article-title":"Hemodynamic effects of propranolol with spironolactone in patients with variceal bleeds:a randomized controlled trial","volume":"14","author":"De","year":"2008","journal-title":"World J Gastroenterol"},{"key":"R6-2-20240828","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","article-title":"A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism","volume":"29","author":"Parthasarathy","year":"2011","journal-title":"J Hypertens"},{"key":"R7-2-20240828","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J Biol Chem"},{"key":"R8-2-20240828","doi-asserted-by":"crossref","first-page":"e0254","DOI":"10.1097\/MD.0000000000010254","article-title":"The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure:A systematic review and meta-analysis","volume":"97","author":"Pei","year":"2018","journal-title":"Medicine (Baltimore"},{"key":"R9-2-20240828","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/164_2016_76","article-title":"Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases:Comparison at bench and bedside","volume":"243","author":"Kolkhof","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"R10-2-20240828","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on chronic kidney disease outcomes in Type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"R11-2-20240828","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","article-title":"ARTS-DN Japan study group. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy","volume":"31","author":"Katayama","year":"2017","journal-title":"J Diabetes Complications"},{"key":"R12-2-20240828","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R13-2-20240828","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4103\/ijem.IJEM_789_20","article-title":"Efficacy and safety of once weekly thyroxine as compared to daily thyroxine in managing primary hypothyroidism:A systematic review and meta-analysis","volume":"25","author":"Dutta","year":"2021","journal-title":"Indian J Endocr Metab"},{"key":"R14-2-20240828","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate healthcare interventions:explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"R15-2-20240828","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE:An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R16-2-20240828","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1253\/circj.CJ-16-0122","article-title":"A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and\/or chronic kidney disease","volume":"80","author":"Sato","year":"2016","journal-title":"Circ J"},{"key":"R17-2-20240828","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy:A randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"R18-2-20240828","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease:A randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"R19-2-20240828","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"R21-2-20240828","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","article-title":"Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes","volume":"78","author":"Filippatos","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R22-2-20240828","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_376_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:07:48Z","timestamp":1787756868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_376_21"}},"subtitle":["A Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijem.ijem_376_21","relation":{},"ISSN":["2230-9500"],"issn-type":[{"value":"2230-9500","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}